AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Fan, Jia
Ren, Zhenggang
Hsu, Chiun
Guo, Yabing
Song, Tianqiang
Wang, Wentao
Chao, Yee
Gao, Yujuan
Li, Vincent
Ferro, Salvatore
Yen, Chia-Jui
机构：
[1] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[4] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[5] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China
[6] Taipei Vet Gen Hosp, Taipei, Taiwan
[7] BeiGene Co Ltd, Shanghai, Peoples R China
[8] BeiGene Inc, San Mateo, CA USA
[9] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4172
引用
收藏
页数：1
相关论文
共 8 条
  • [1] AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus antiprogrammed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC)
    Fan, Jia
    Ren, Zhenggang
    Hsu, Chiun
    Guo, Yabing
    Song, Tianqiang
    Wang, Wentao
    Chao, Yee
    Gao, Yujuan
    Li, Bai
    Ferro, Salvatore
    Yen, Chia-Jui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) plus tislelizumab (TIS)+BAT1706 (bevacizumab biosimilar) versus TIS+BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ren, Z.
    Huang, Y.
    Guo, Y.
    Hou, M. M.
    Wang, W.
    Kuang, M.
    Hao, C.
    Wang, W.
    Zhang, Y.
    Song, T.
    Dai, C.
    Hsing-Tao, K.
    Li, V.
    Abdrashitov, R.
    Wang, L.
    Fan, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S594 - S594
  • [3] AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
    Lu, Y.
    Gong, Y.
    Kang, J-H.
    Ree, J. Whan
    Chen, X.
    Lin, X.
    Zhang, J.
    Borghaei, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S103 - S103
  • [4] AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).
    Socinski, Mark A.
    Spira, Alexander I.
    Paz-Ares, Luis G.
    Reck, Martin
    Lu, Shun
    Nishio, Makoto
    Li, Jiang
    Zhou, Yunfei
    Rhee, Joon Whan
    Duque, Sandra Chica
    Yu, Xinmin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
    Xu, Rui-hua
    Kim, Sung-Bae
    Tougeron, David
    Zuo, Yunxia
    Yang, Haiyuan
    Zhang, Juan
    Shi, Jingwen
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).
    Xu, Rui-Hua
    Kim, Sung-Bae
    Tougeron, David
    Zuo, Yunxia
    Yang, Haiyuan
    Zhang, Juan
    Shi, Jingwen
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Liberty-201: Maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC)
    Lenz, Heinz-Josef
    Yuan, Ying
    Li, Vivian
    Zhang, Juan
    Jamal, Lubna
    Lin, Xiao
    Zhu, Fuxiang
    Strickler, John H.
    CANCER RESEARCH, 2024, 84 (07)
  • [8] BGB-A317-LBL-007-202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC)
    Park, Sook Ryun
    Chen, Ming-Huang
    Dechaphunkul, Arunee
    Ding, Ningning
    Lin, Xiao
    Zhang, Jinghui
    Li, Vivian
    Li, Qiao
    Ba, Yi
    CANCER RESEARCH, 2024, 84 (07)
1